Biomed plans to conduct two Phase 3 clinical trials programs for NA-831:
(1) The COGNITION Program for the treatment of 375 patients with mild and moderate Alzheimer’s disease over 12 months. Age group: 65- 80 years of age.
(2) The PREVENTION Program for the prevention of 550 subjects, asymptomatic from a high risk population over 24 months. Age group: 45-70 years of age.
These trials follow strict scientific standards and regulatory requirements to protect patients and help produce reliable results.
Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the clinical trials.
The Phase 3 clinical trials have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for prophylaxis and treatment of early onset of Covid-19.
Clinicaltrials.gov-identifier
NCT04540185
In the Phase 3 clinical trial of BioCovax, we have studied the safety and efficacy of oral polio vaccine with and without NA-831 versus placebo, with 3,600 participants in many centers in the US, Canada, UK, Australia, New Zealand, China, Vietnam, and Brazil.
A product brochure of BioCovax can be downloaded here.
Biomed has developed Biomedivir™, which is comprised of our neuroprotective agent called NA-831 and Atazanavir. Atazanavir was approved by the FDA for prevention and treatment of HIV/AIDS treatment, and is now a generic drug. Biomedivir™ is an oral formulation which can be used as a prophylaxis and treatment of early onset of Covid-19.
Biomed plans to launch the Phase 2/3 trials of Biomedivir™ for the prophylaxis and treatment of early onset of Covid-19 in 2022.
Please contact us for study locations near you. Contact information is provided so you can reach out to them to find out more and schedule a visit.
For further information about our products, please contact us. Contact us
Traneuroci™ or NA-831 provides neuroprotection and catalyzing the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed.
Learn more
Biomed Digital is harnessing the power of wearable technology and machine learning to create a digital phenotype that helps clinicians to diagnose early onset of Alzheimer’s disease.
Learn more
Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also conduct Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19
Learn more
Vineurocin (NA-704) is an injectable drug, to regenerate new neurons, and reducting of muscular spasticity, a strong candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.
Learn more
Combination therapy of NA-831 and an antiviral drugs such as Atazanavir, Remdesivir (Gilead Sciences) and anti-inflammatory such as Dexaneurosone and Ivermectin can enhance the effectiveness of the treatment of Covid-19.
Learn more